Byooviz, a Samsung Bioepis biosimilar version of the eye treatment Lucentis, was approved for sale in the United States, the company said Wednesday.
Samsung Bioepis said Monday that a five-year follow-up study of the company's biosimilar product Ontruzant confirmed its safety and long-term effectiveness.
Byooviz, a Samsung Bioepis biosimilar referencing ophthalmology treatment Lucentis, was approved for sale in the EU, the company said Monday.
Dong-A ST and Tokyo’s Meiji Seika Pharma have signed a deal with Ahmedabad, India’s Intas Pharmaceuticals to license DMB-3115, biosimilar referencing psoriasis treatment Stelara, the Korean company announced Wednesday.
SB17, a Samsung Bioepis biosimilar referencing psoriasis treatment Stelara, is in Phase 3 clinical trials, the company said Tuesday.
Celltrion’s biosimilar CT-P17 was approved for sale in Europe, the company said Monday. The final nod from the European Commission came on Feb. 11. CT-P17 is a biosimilar of Abbvie’s Humira, or adalimumab.
Remsima SC, Celltrion Healthcare’s self-applicable biosimilar of infliximab, will likely be available for patients in Europe suffering from ailments beyond what the drug was originally approved to treat.
Celltrion Healthcare introduced Remsima SC in the Netherlands, the third European market where it has rolled out the biosimilar. Celltrion Group sales company announced Thursday that it began selling Remsima SC in the country on April 27.